Can biosimilars help achieve the goals of US health care reform?

Ralph V. Boccia(Center for Cancer and Blood Disorders), Gilberto Lopes(University of Miami), Robert Popovian(Pioneer (United States)), Ira Jacobs(Amgen (United States))

Cancer Management and Research

June 1, 2017

10.2147/cmar.s133442

Cited by 20

Related Papers

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

|The Lancet|2019|3.4k

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

|The Lancet|2020|1.8k

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

|Breast Cancer Research and Treatment|2017|761

Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia

|New England Journal of Medicine|2010|425

Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial

|The Lancet Oncology|2013|387